J. Silvio Gutkind

Associate Director, Basic ScienceJ. Silvio Gutkind received his Ph.D. in Pharmacy and Biochemistry from the University of Buenos Aires, Argentina. He was trained as a post-doctoral fellow at the NIMH and NCI, and joined the National Institute of Dental and Craniofacial Research (NIDCR), NIH, where he is currently the Chief of the Oral and Pharyngeal Cancer Branch. Dr. Gutkind is a national and international leader in the study of basic signal transduction mechanisms in cancer. He is recognized for his pioneering research aimed at unraveling the complexity of the intracellular signaling circuitry by which cell surface receptors and Rho GTPases control the nuclear expression of growth promoting genes, thereby promoting normal and malignant growth. His recent studies have addressed the role of mutant G proteins and G protein coupled receptors in cancer initiation, with emphasis on ocular melanoma, colon and skin cancer, and AIDS-malignancies. His multidisciplinary team has also made outstanding contributions to the study of the aberrant signaling circuitries driving head and neck cancer progression, including the seminal finding that most head and neck cancer lesions display persistent activation of the PI3K–AKT–mTOR pathway. His team is now exploiting the emerging information for the development of novel mechanism-based anti-cancer therapies. In particular, Dr. Gutkind is currently leading a multi-institutional effort aimed at exploring the clinical benefits of trea...
Source: PHRMA - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

A video of the very sweet moment a young Tennessee girl learned she was cancer-free has gone viral.
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
Authors: Emmanuel S, Jornayvaz FR Abstract Discovered 20 years ago, Fibroblast Growth Factor (FGF) 19, and its mouse ortholog FGF15, were the first members of a new subfamily of FGFs able to act as hormones. During fetal life, FGF15/19 is involved in organogenesis, affecting the development of the ear, eye, heart and brain. At adulthood, FGF15/19 is mainly produced by the ileum, acting on the liver to repress hepatic bile acid synthesis and promote postprandial nutrient partitioning. In rodents, pharmacologic doses of FGF19 induce the same anti-obesity and anti-diabetic actions as FGF21, these metabolic effects bei...
Source: Endocrine Reviews - Category: Endocrinology Tags: Endocr Rev Source Type: research
STEFAN KARL STEFANSSON, the LazyTown actor that starred as Robbie Rotten, has died after a battle with bile duct cancer. Bile duct cancer symptoms include  itchy skin and weight loss - these are the warning signs to look out for.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Authors: Govender K, Masebo WGB, Nyamaruze P, Cowden RG, Schunter BT, Bains A Abstract The global commitment to ending the AIDS epidemic by 2030 places HIV prevention at the centre of the response. With the disease continuing to disproportionately affect young populations in the Eastern and Southern African Region (ESAR), particularly adolescent girls and young women, reducing HIV infections in this group is integral to achieving this ambitious target. This paper examines epidemiological patterns of the HIV epidemic among adolescents and young people, indicating where HIV prevention efforts need to be focused (i.e....
Source: Open AIDS Journal - Category: Infectious Diseases Tags: Open AIDS J Source Type: research
Authors: Timmerman C, Taveras L, Huerta S Abstract INTRODUCTION: The standard of care for locally advanced rectal cancer includes neoadjuvant chemoradiation with subsequent total mesorectal excision. This approach has shown various degrees of response to neoadjuvant chemoradiation (ranging from complete response to further tumor growth), which have substantial prognostic and therapeutic implications. A total regression of the tumor is a predictor of superior oncologic outcomes compared to partial and non-responders. Further, this concept has opened the possibility of nonoperative strategies for complete responders ...
Source: Expert Review of Molecular Diagnostics - Category: Laboratory Medicine Tags: Expert Rev Mol Diagn Source Type: research
Authors: El-Chaer WK, Moraes CF, Nóbrega OT Abstract Although prostate cancer (PCa) is the sixth most common type of neoplasm in the world and the second in prevalence among men (10% of all cases), there is shortage of studies focused on primary prevention of the disorder as well as little understanding on its pathophysiology. Currently, the PCa screening tools are the prostate specific antigen (PSA) dosage conjugated to rectal examination and confirmed by prostate biopsy. Despite the name, the PSA presents reduced specificity, being necessary the identification of new biomarkers that allow an earlier and mo...
Source: Journal of Aging Research - Category: Geriatrics Tags: J Aging Res Source Type: research
In recent years, researchers working on forms of telomerase gene therapy have produced evidence to show that increased levels and activity of telomerase does not raise cancer risk in mice. The open access paper and publicity materials noted below report the latest example. Extra telomerase increases the sort of activities that are beneficial in the context of improved regenerative capacity, but might be thought to raise the risk of cancer when they take place in the damaged environment of old tissue. This means more stem cell activity, more cellular replication, and so forth. Somatic cells are limited in the degree ...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
SAN FRANCISCO - A California jury on Aug. 10 found that Monsanto Co. acted with malice regarding its failure to warn of the damages associated with glyphosate, the active ingredient in Roundup, and awarded $289,254,882.32 in damages in the bellwether case of a man who said his repeated exposure to the herbicide caused his cancer (DeWayne Johnson v. Monsanto Company, No. CGC 16550128, Calif. Super., San Francisco Co.).
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - Category: Medical Law Source Type: news
SAN FRANCISCO - The California judge who presided over the trial in which a jury awarded $289 million to a man who said Monsanto Co. was liable for causing his cancer as a result of exposure to glyphosate confirmed Aug. 17 that the verdict was unanimous and that she was not expressing a vote when she polled the jury, as has been claimed by a Monsanto executive in an interview with the British Broadcasting Co. (BBC).
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - Category: Medical Law Source Type: news
SAN FRANCISCO - The attorney representing a California man who contends that he developed cancer as a result of exposure to glyphosate on Aug. 7 presented closing arguments in the first trial related to the herbicide Roundup and asked a jury to "change the world" by holding Monsanto Co. accountable for its "reckless disregard for human health," which he said warranted an award of more than $412.25 million in combined damages (DeWayne Johnson v. Monsanto Company, No. CGC 16550128, Calif. Super., San Francisco Co.).
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - Category: Medical Law Source Type: news
More News: Biochemistry | Cancer | Cancer & Oncology | Cancer Therapy | Colon Cancer | Colorectal Cancer | Genetics | Head and Neck Cancer | HIV AIDS | Melanoma | Men | Oral Cancer | Pharmaceuticals | Pharyngeal Cancer | Skin | Skin Cancer | Study